GLP-1 Market
LLY $1415.55 ▼ -1.1% NVO $40.70 ▼ -2.2% PFE $28.47 ▼ -1.4% VKTX $26.88 ▲ +0.3% KLRA $12.20 ▼ -2.9% GPCR $18.17 ▼ -2.2% RHHBY $60.28 ▼ -1.1%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Empagliflozin + Liraglutide

Company
University Health Network, Toronto
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 18, 2026

Trial details
  • Completed NCT NCT04535960

    Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

    Not yet reported University Health Network, Toronto 6 participants Est. completion 2021-03-16 1 site
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Empagliflozin + Liraglutide, Empagliflozin 25 MG + Liraglutide 1.8 MG, Generic names are above, listed, Liraglutide 1.8 MG + Empagliflozin 25 MG

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.